Zayed Sustainability Prize Opens Global Call for Transformative Solutions
10.2.2025 14:21:00 CET | Business Wire | Press release
The US $5.9 million fund empowers small and medium sized enterprises, nonprofits, and high schools to develop sustainable solutions and transform their communitiesAcross 6 key categories – Health, Food, Energy, Water, Climate Action and Global High Schools – winners will be recognised for their groundbreaking impact and receive the prestigious award
The UAE’s Zayed Sustainability Prize, a portfolio entity of Erth Zayed Philanthropies which has impacted 400 million lives worldwide by advancing innovative solutions to pressing global challenges, has officially announced its call for submissions for 2026. Marking 17 years of continued support and empowerment for the next generation of sustainability champions, the Prize invites small to medium enterprises (SMEs), nonprofit organisations, and high schools to submit their projects in six distinct categories: Health, Food, Energy, Water, Climate Action, and Global High Schools.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250210057043/en/
Zayed Sustainability Prize Opens Global Call for Transformative Solutions (Photo: AETOSWire)
In 2024, the Prize received 5,980 submissions from 156 countries, reflecting a growing international commitment to sustainable development. As the 2026 submission cycle begins, the Prize aims to build on this momentum and seize the unique opportunity at the Nexus of Next, a dynamic convergence of technological innovation, human ingenuity, and strategic vision to accelerate progress worldwide.
Commenting on the launch, H.E. Dr. Sultan Ahmed Al Jaber, UAE Minister of Industry and Advanced Technology and Director General of the Zayed Sustainability Prize said: “The Zayed Sustainability Prize honours Sheikh Zayed’s vision of advancing inclusive sustainable and humanitarian development. By supporting projects that harness new technologies to improve lives and drive prosperity in local communities, the Prize places people at the heart of progress, and demonstrates the role of the Nexus of Next in accelerating socio-economic growth worldwide.”
The Prize will reward US $1 million to the winners of each organisational category, while those in the Global High Schools category - split into six world regions – can claim up to US $150,000 to deploy or further expand their project. This funding has already enabled tangible progress and improved living conditions in vulnerable areas around the world, from expanding healthcare access in Southeast Asia to reducing food poverty in Sub-Saharan Africa.
The most recent Zayed Sustainability Prize winners were recognised at an Awards Ceremony in Abu Dhabi in the presence of H.H. Sheikh Mohamed bin Zayed, President of the United Arab Emirates, alongside 11 Heads of State and several Ministers and business leaders. These distinguished guests witnessed the promise and impact of each winner, as well as the UAE’s firm commitment to providing a platform for such solutions to grow.
For the 2026 cycle, applicants in the Health, Food, Energy, Water and Climate Action categories must prove that their solution is improving access to essential services in their communities, and that they can implement a long-term vision for better living and working conditions. For the Global High Schools category, projects should be led by students and must demonstrate innovative approaches to address sustainability challenges.
To encourage a broader range of organisations and high schools to participate, the Prize accepts submissions in multiple languages, including Arabic, Chinese, English, French, Russian, Spanish, and Portuguese.
The evaluation of each submission to the Prize consists of a rigorous, three-stage process. First, due diligence is conducted on all submissions to ensure that they meet the Prize’s evaluation criteria of Impact, Innovation, and Inspiration. This identifies the qualified entries and results in the selection of eligible candidates. Following this, evaluations are undertaken by a Selection Committee consisting of category-specific panels of independent international experts. From this shortlist of candidates, the finalists are chosen and then sent to the Prize Jury who unanimously elect the winners across all six categories.
Winners of the Zayed Sustainability Prize will be announced at an Awards Ceremony in 2026.
For more details and to submit your application, please click here.
About the Zayed Sustainability Prize
The Zayed Sustainability Prize, a portfolio entity of Erth Zayed Philanthropies, is the UAE’s pioneering award for innovative solutions to global challenges.
A tribute to the legacy and vision of the UAE’s founding father, Sheikh Zayed bin Sultan Al Nahyan, the Prize aims to drive sustainable development worldwide.
Each year, across the Health, Food, Energy, Water, Climate Action and Global High Schools categories, the Prize rewards organisations and high schools for their groundbreaking solutions to our planet’s most pressing needs.
Through its 128 winners, in 17 years, the Prize has positively impacted over 400 million lives across the globe, inspiring innovators to amplify their impact, and chart a sustainable future for all.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20250210057043/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom